HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling

Agile Therapeutics Inc's AGRX Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.
H.C. Wainwright expects prescription acceleration soon with non-retail channel ramping and Washington forcing coverage with the Affordable Care Act provisions assuring women straightforward, no-cost access to contraceptives.
The analyst has raised the price target to $5 from $2.50 and reiterated a Buy.
Related: Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla.'
Management indicates that Afaxys with meaningful institutional orders were likely also stirred by Roe. Large accounts, having switched to Twirla from high-dose Xulane, are still working down the remaining Xulane inventory.
The analyst thinks that if Twirla accelerates along with a lower cost-base, exiting this year, 2024 could potentially break even and re-rate the shares.
Also, additional consolidation in the revenue-generating women's health space, thus potential Agile strategic optionality.
Price Action: AGRX shares are down 3.70% at $0.66 during the market session on the last check Tuesday.